Medicare GLP-1 Bridge: Who Qualifies, the $50 Copay and How to Start

The Medicare GLP-1 Bridge can make an eligible weight-management prescription cost $50 a month. The important first question is whether your prescription belongs in this program or in your regular Part D plan. Bridge operates separately from the Part D benefit; it is not a new $50 price for every Medicare GLP-1 prescription. CMS currently lists July 1, 2026, through December 31, 2027, as the demonstration period.¹

For a beneficiary or caregiver, the useful starting point is a conversation with the prescribing office and pharmacy—not buying a new telehealth membership. Bring your drug-plan card, medication history and the records from when GLP-1 treatment began. Those records can help the office answer the eligibility questions without guessing.

First, check your Medicare coverage

You need eligible Part D enrollment. Medicare lists standalone prescription drug plans, Medicare Advantage coordinated-care plans with drug coverage, Special Needs Plans, employer/union group waiver plans and LI NET among the eligible arrangements. Original Medicare alone is not enough.²

Some less common arrangements, including PACE and private fee-for-service plans, do not qualify on their own; CMS specifies an exception where the person also has an eligible standalone prescription drug plan. If the name on your card does not make the plan type clear, ask 1-800-MEDICARE or a State Health Insurance Assistance Program counselor to identify it before pursuing an application.³

The three clinical eligibility routes

Applicants must be at least 18. At the start of GLP-1 therapy, one of these routes must apply: BMI of at least 35; BMI of at least 30 with heart failure with preserved ejection fraction, qualifying uncontrolled hypertension or stage 3a-or-higher chronic kidney disease; or BMI of at least 27 with prediabetes, previous heart attack, previous stroke or symptomatic peripheral artery disease.²

“Uncontrolled hypertension” has a specific meaning here: systolic pressure above 140 or diastolic above 90 despite concurrent treatment with two blood-pressure medicines. The prescriber also confirms weight-management use alongside structured nutrition and physical activity, with the form allowing for activity that is not clinically appropriate.⁴

The relevant BMI is the one at treatment initiation, including treatment started before Bridge or Medicare enrollment. A lower BMI after treatment does not by itself settle eligibility. Ask the office to locate the original dated measurement; do not substitute an estimated starting weight.⁵

When ordinary Part D comes first

CMS excludes beneficiaries with Part D-coverable type 2 diabetes, moderate-to-severe obstructive sleep apnea, or qualifying noncirrhotic MASH with moderate-to-advanced liver fibrosis. Its plan guidance also excludes people who received a GLP-1 through Part D in calendar year 2026. A prescription for a Part D-coverable use stays with the plan even when the drug is off its formulary; the plan's exception process still matters.⁶

Cardiovascular history needs particular care. A previous heart attack can fit a Bridge eligibility route, but a prescription intended to reduce major cardiovascular events belongs with Part D, even if weight reduction is also intended. The prescriber must determine and accurately document the actual indication. Bridge is not a reason to alter or conceal a diagnosis.⁵ Our insurance coverage guide explains the wider distinction between a covered use and a covered prescription.

Check the product, including its device

Medicare currently lists Foundayo tablets, Wegovy injections and tablets, and Zepbound KwikPen. Zepbound single-dose pens and single-dose vials are excluded from Bridge.² That last distinction is easy to miss when a conversation uses only the brand name. Ask the pharmacy to confirm the exact product being billed. Our Mounjaro and Zepbound comparison provides background on the brands; it does not establish your program eligibility.

The prescription starts at the pharmacy

Have the prescribing office send the prescription to the pharmacy. The pharmacy submits the Bridge claim, then requests prior authorization from the prescriber, typically within 24–72 hours. The office completes the clinical attestation electronically or by fax. CMS says the decision is communicated to the prescriber within 72 hours of submission and mailed to the patient.³

Do not confuse the initial Bridge claim rejection requesting authorization with a final clinical denial. The current form requires that initial pharmacy claim before the prescriber submits the authorization. An ordinary Part D denial is not a prerequisite, and starting the authorization too early can produce a “patient not found” error.⁴⁵

If nothing moves, ask the pharmacy whether it submitted to Bridge and ask the office whether it received the authorization request. These are more useful questions than “Has Medicare approved it?” CMS directs prescribers who have not received the request after 72 hours to its fax-form process.³

What the $50 does—and does not—cover

The Part D deductible does not apply to Bridge drugs. The $50 copay does not count toward Part D true out-of-pocket spending, and Extra Help's low-income subsidy does not reduce it.¹ Bridge dispensing is also outside the Medicare Prescription Payment Plan.⁶

Only 28-day or 30-day fills are covered. Refills generally do not need another authorization unless the patient changes drugs.³ Medicare says authorization lasts through December 31, 2027, unless you change GLP-1s.² For budgeting, six $50 fills total $300 in medication copays; six 28-day fills cover 168 days, not six calendar months. Ask separately about appointments and supplies. CMS says KwikPen needles are not covered by Bridge.⁵

If Bridge says no

CMS states that Bridge has no appeals process. The prescriber may resubmit when information was entered incorrectly or when updated or additional information is available. That is different from an ordinary Part D denial, which retains its own appeal rights.⁵⁶

Keep the denial and ask which eligibility answer caused it. An incorrect date or missing record calls for a different response from an excluded plan type or a Part D-coverable indication. Our prior-authorization denial guide helps sort those paths; the six-month cost comparison helps assess alternatives if coverage remains unavailable.

Source check and rule changes

Checked October 6, 2026 against CMS and Medicare publications. This first edition reflects the extension through December 2027, current product formats and the pharmacy-first workflow. It is a review of published program rules, not an individual eligibility determination or a clinician or benefits-specialist review. Use the linked CMS sources below and 1-800-MEDICARE to resolve a case-specific question before committing to treatment costs.